当地时间6月18日，为了积极主动融入全球创新药物体系，提高国家科技计划对外开放水平，最大限度利用好全球创新药物研发资源，北京大学深圳研究生院与美国斯克里普斯研究所在美国旧金山签署备忘录，设立合作机构共同开展药物研发。广东省委常委、深圳市委书记王伟中见证签约，北大深研院院长吴云东与美国斯克里普斯研究所董事长彼得·舒尔茨签署了协议。
在广东省委常委、深圳市委书记王伟中(后排中间)见证下，北京大学深圳研究生院院长吴云东教授（前排右）与斯克里普斯研究所总裁彼得·舒尔茨教授（前排左）代表双方签署合作协议
根据协议，双方将在以下方面通力合作：创造世界一流生物医学研究的基础条件，提高科研实力，推动创新药物研发及商品化。为此，双方同意成立一家非营利研究机构，从事生物医学领域基础性和早期的转化医学研究, 以及培养生物医药领域的科学家。该项合作将通过美国斯克里普斯研究所在转化医学研发领域的研发优势与北大深研院在药物化学和合成化学国际一流的研发水平相结合，打造创新药物的完整产业链，提升双方药物研发能力和水平。
当天，王伟中书记会见了舒尔茨董事长。深圳市国资委主任彭海斌，深圳市外办主任蔡颖，深圳市经信委主任刘胜，深圳市科创委主任梁永生，深圳市投资控股公司董事长王勇健，北大深圳研究生院吴云东院长，杨震、涂欢副院长和加州生物医学研究所（斯克里普斯下属的创新药研究所）首席研究员与中国合作部总监沈卫军等陪同会见，并共同出席了深圳湾硅谷科技创新中心在美国加州圣克拉拉市举行的揭牌仪式。
王伟中书记会见了舒尔茨董事长
背景介绍：
美国斯克里普斯研究所（The Scripps Research Institute, 简称TSRI），创办于1924年，是美国最大的私立非营利性质的研究所。该研究所目前已经是全美最大的生命科学机构。该研究所代表了世界领先的生物医药研究中心，同时也建立了加速基础生物医学研究转化的创新药物基础设施和专业技术平台。这种组合已经成功地开发出了一系列新药候选物。2017 年自然杂志评选TSRI在制药领域全球科学创新力排名第一。该所董事长彼得·舒尔茨教授是美国国家科学院、国家医学院院士，沃尔夫化学奖和苏威奖得主，是公认的药物研发及产业化的顶尖领袖级人物。
北大深圳化学生物学与生物技术学院在化学合成方面成绩斐然，在新药研发积累了重要经验，拥有深圳唯一的院校类国家重点实验室“省部共建肿瘤化学基因组学国家重点实验室”。学术带头人，中国科学院院士吴云东是世界公认的理论计算化学家。
鉴于该合作将有助于在深圳市建立一个世界级的具有转化医学研究能力和临床试验能力的转化医学研究所、将对中美生物医药产业发展和人类健康产生积极影响, 深圳市将支持北大深研院与美国斯克里普斯研究所的合作，包括推进基于由斯克里普斯研究所提供（包括癌症、神经退行性疾病和老年病、糖尿病和肥胖、肝病和肺病等疾病领域）的一系列临床前候选物的后续研发经费和研究所的建设经费。
On June 18，local time, in order to actively contribute to innovative drug discovery and development, increase the level of collaboration within the international research community, and make the best use of resources for global public health, the Shenzhen Graduate School of Peking University and the Scripps Research Institute signed a memorandum of understanding (MOU) in San Francisco to set up a joint institute to carry out translational research and drug development. WANG Weizhong, member of the standing committee of Guangdong Provincial CPC Committee and secretary of the Shenzhen Municipal CPC Committee, witnessed the signing of the agreement between WU Yundong, Chancellor of the Shenzhen Graduate School of Peking University, and Peter Schultz, President and CEO of the Scripps Research Institute.
According to the agreement, the two sides will work together to create a world-class biomedical research enterprise that creates innovative drugs for the treatment of cancer, metabolic and inflammatory diseases, degenerative diseases of aging and infectious disease. To this end, the two sides agreed to set up a non-profit research institute to conduct basic and early translational biomedical research, and train scientists in biomedical research.
This collaboration will combine the research capabilities of the Scripps Research Institute in the field of translational medicine with the first-class research programs in pharmaceutical chemistry and synthetic chemistry in the Shenzhen Graduate School of Peking University. The vision is to create a self-sustaining pipeline of innovative drugs for the worldwide community.
On the same day, Secretary WANG Weizhong met with Peter Schultz, WU Yundong, vice Chancellors YANG Zhen and TU Huan of the Shenzhen Graduate School of Peking University and Weijun Shen, Principal Investigator and Director of China Partnership of Calibr (a drug discovery affiliate of TSRI), and jointly attended the opening ceremony of the Shenzhen Bay Silicon Valley Scientific Research and Innovation Center in Santa Clara, California.
Background:
Founded in 1924, The Scripps Research Institute is one of the largest private non-profit research institutions in the United States. The institute represents a world-leading biomedical research institution with infrastructure and expertise to accelerate the translation of basic biomedical research into new medicines. Scripps has produced new drugs that have impacted cancer, autoimmune diseases and neurodegenerative diseases. In 2017, Nature magazine ranked The Scripps Research Institute as the leading scientific and technology innovator in the world. The President Peter Schultz is an academician of the National Academy of Sciences and the National Academy of Medicine, and a Wolf and Solvay Prize winner; he is recognized as a leader in chemical biology and drug R & D.
The Shenzhen Graduate School of Peking University has made outstanding achievements in medicinal chemistry and chemical synthesis and has accumulated important experience in the research and development of new drugs, and recently has been approved as the state key laboratory of cancer genomics. WU Yundong, academician of the Chinese Academy of Sciences (CAS), is a universally recognized theoretical computational chemist.
Because this collaboration will contribute to the establishment of a world- class research capability in translational medicine in Shenzhen and will positively impact the biotechnology industry and human health in China and around the world, Shenzhen will support the collaboration between Shenzhen Graduate School of Peking University and the Scripps Research Institute. This support will include funding for follow-up research and development based on a range of pre-clinical candidate drugs initially developed by the Scripps Research Institute as well as funding for the establishment of the institute.
